Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
10
×
boston blog main
fda
10
×
life sciences
national blog main
boston top stories
clinical trials
deals
investing
national top stories
san francisco blog main
roche
san francisco top stories
alexion pharmaceuticals
biotech ipos
hepatitis b
medical device
new york blog main
new york top stories
nonalcoholic steatohepatitis
perceptive advisors
rare disease drugs
startups
venture capital
480 biomedical
abbott laboratories
abbvie
access biotechnology
access industries
adel malek
akouos
aligos therapeutics
alnylam pharmaceuticals
amyotrophic lateral sclerosis (als)
anemia
arsenal medical
astellas pharmaceuticals
atlas ventures
aton partners
What
medicines
drug
therapeutics
developing
ipo
million
new
raised
treat
body
candidate
company
disease
fda
lead
muscle
pharma
pharmaceuticals
research
roche
team
way
absorb
address
advance
affects
alternative
americans
analytics
anemia
approval
approved
autoimmune
biofourmis
biotech
biotechs
blood
blueprint
brain
brings
Language
unset
10
×
Current search:
boston
×
unset
×
fda
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds